(Q42927136)

11 November 2017

title

A method for evaluating treatment switching criteria in multiple sclerosis (English)

1 reference

11 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20736245

22 June 2024

6

Tanuja Chitnis

1 reference

11 November 2017

5

Howard Weiner

1 reference

11 November 2017

James Stankiewicz

3

1 reference

11 November 2017

Guy Buckle

4

1 reference

11 November 2017

Brian C. Healy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20736245

22 June 2024

Bonnie I. Glanz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20736245

22 June 2024

Howard Weiner

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20736245

22 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20736245

22 June 2024

publication date

24 August 2010

1 reference

full work available at URL

11 November 2017

http://msj.sagepub.com/cgi/content/abstract/16/12/1483

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20736245

http://journals.sagepub.com/doi/pdf/10.1177/1352458510379245

22 June 2024

1 reference

https://api.crossref.org/works/10.1177/1352458510379245

Multiple Sclerosis Journal

22 June 2024

published in

1 reference

11 November 2017

volume

16

1 reference

11 November 2017

issue

12

1 reference

11 November 2017

page(s)

1483-1489

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Identifying and treating patients with suboptimal responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Estimating causal effects from epidemiological data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Is it time to use observational data to estimate treatment effectiveness in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Doubly robust estimation in missing data and causal inference models

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510379245

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1177/1352458510379245

Modern Applied Statistics with S

22 June 2024

20

1 reference

https://api.crossref.org/works/10.1177/1352458510379245

22 June 2024

Identifiers

1 reference

11 November 2017

1 reference